ISLH is committed to ensuring an up to date inventory of guidelines that support the Hematology Laboratory community. You may view our inventory of guidelines by selecting a category/topic below. Please note that the search/sort options will only include guidelines for the currently selected category/topic.
Guideline Title | Organization | Year | Action |
---|---|---|---|
ISO 15189:2022 Medical Laboratories – Requirements for quality and competence |
ISO |
2022 |
|
International normalized ratio and activated partial thromboplastin time testing |
2022 |
||
International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing |
ICSH |
2021 |
|
Recommendations for estimating measurement uncertainty in medical laboratories (ISO 15189 and ISO 20914) |
SIPMeL |
2021 |
|
Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies |
ISTH/SSC |
2021 |
|
Optimal Testing: AACC's Guide to Lab Test Utilization |
AACC |
2020 |
|
Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis |
BSH |
2020 |
|
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases |
BMC |
2019 |
|
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum |
Anticoagulation Forum |
2019 |
|
Croatian Society of Medical Biochemistry and Laboratory Medicine: National recommendations for blood collection, processing, performance and reporting of results for coagulation screening assays prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and D-dimer. |
Croatian Society of Medical Biochemistry and Laboratory Medicine |
2019 |
|
Joint EFLM-COLABIOCLI Recommendation for venous blood sampling |
EFLM-COLABIOCLI |
2018 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Practice guidelines for BRCA1/2 tumour testing in ovarian cancer |
CCMG and Canadian Association of Pathologists |
2022 |
|
Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies |
CAP |
2021 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Assays to quantify fibrinolysis: strengths and limitations. Communication from the ISTH SSC Subcommittee on Fibrinolysis |
ISTH SSC |
2023 |
|
Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: guidance from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2022 |
|
Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee |
ISTH SSC |
2022 |
|
Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies |
ISTH SSC |
2022 |
|
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline |
United Kingdom Haemophilia Centre Doctors’ Organisation |
2022 |
|
Heparin Resistance — Clinical Perspectives and Management Strategies |
|
2021 |
|
Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH |
ISTH SSC |
2021 |
|
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulant |
ICSH |
2021 |
|
Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Update of the guidelines for lupus anticoagulant detection and interpretation |
ISTH SSC |
2020 |
|
Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH |
ISTH SSC |
2020 |
|
Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH |
ISTH SSC |
2019 |
|
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants |
ICSH |
2018 |
|
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH |
ISTH SSC |
2018 |
|
European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative |
NIH |
2017 |
|
Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations |
NIH |
2017 |
|
Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL |
Blood Transfusion |
2017 |
|
Internal quality control practices in coagulation laboratories: recommendations based on a patterns-of-practice survey |
IQMH |
2015 |
|
Diagnosis of inherited platelet function disorders: Guidance from the SSC of the ISTH |
ISTH |
2015 |
|
Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH |
ISTH |
2014 |
|
Validation of hemostasis and coagulation assays: recommendations and guidelines |
Independent authors (STH) |
2014 |
|
The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology |
UKHCDO / BCSH |
2014 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Evidence to Improve Care: Sickle Cell Disease – Care for People of All Ages |
Health Quality Ontario |
2023 |
|
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
ASH |
2020 |
|
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain |
ASH |
2020 |
|
ICSH recommendations for assessing automated high-performance liquid chromatography and capillary electrophoresis equipment for the quantitation of HbA2 |
ICSH |
2015 |
|
ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders |
ICSH |
2015 |
|
ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes |
ICSH |
2011 |
|
ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes |
ICSH |
2011 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. |
WHO |
2016 |
|
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology |
CAP |
2016 |
|
ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features |
ICSH |
2015 |
|
ICSH guidelines for the standardization of bone marrow immunohistochemistry |
ICSH |
2015 |
|
ICSH guidelines for the evaluation of blood cell analyzers including those used for differential leucocyte and reticulocyte counting |
ICSH |
2014 |
|
ICSH guidelines for the verification and performance of automated cell counters for body fluids |
ICSH |
2014 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology |
ISTH SSC |
2021 |
|
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders |
ICCS/ESCCA |
2018 |
|
Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group |
PBC |
2016 |
|
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 |
ESCCA |
2011 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH |
ISTH SSC |
2022 |
|
Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH |
ISTH SSC |
2022 |
|
Antithrombotic agents in patients with COVID-19 |
CMAJ |
2022 |
|
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S |
2022 |
||
COVID-Inflicted Coagulopathy: Expert Consensus on Management with Novel Oral Anticoagulants in India |
2021 |
||
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 |
Ontario Science Table |
2022 |
|
Alert to Health Care Professionals about a potential drug-drug interaction between Paxlovid and anticoagulants |
Thrombosis Canada |
2022 |
|
WHO recommends two new drugs to treat COVID-19 |
WHO |
2022 |
|
The COVID-19 Treatment Guidelines Panel's Statement on Anticoagulation in Hospitalized Patients With COVID-19 |
NIH |
2022 |
|
Evidence-Based Recommendations on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies (Casirivimab + Imdevimab, and Sotrovimab) for Adults in Ontario |
Ontario Science Table |
2021 |
|
Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources |
2021 |
||
VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme |
UK Expert Haematology Panel |
2021 |
|
Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19 |
ADD |
2021 |
|
Evidence-Based Use of Therapeutics for Ambulatory Patients with COVID-19 |
Ontario Science Table |
2021 |
|
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 |
Ontario Science Table |
2021 |
|
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) |
NICE |
2021 |
|
Guidance for clinical case management of thrombosis with thrombocytopenia syndrome(TTS) following vaccination to prevent coronavirus disease (COVID-19) |
WHO |
2021 |
|
COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets |
EMA |
2021 |
|
The ISTH Releases Interim Guidance on Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) |
ISTH |
2021 |
|
Laboratory testing for post ChAdOx1 nCOV-19 vaccination VITT: A challenge. Comment on: Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology |
ISTH SSC |
2021 |
|
Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: Communication from the ISTH SSC Subcommittee on Platelet Immunology |
ISTH SSC |
2021 |
|
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in the Outpatient Setting |
COVID-19 Advisory for Ontario |
2021 |
|
Recognizing, managing and reporting vaccineinduced immune thrombotic thrombocytopenia |
2021 |
||
Intensive Care guidance for the management of vaccine induced immune-thrombocytopenia and thrombosis (VITT) |
UK Intensive Care Society and NACCS |
2021 |
|
The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing |
Infectious Diseases Society of America |
2021 |
|
ASH Guidelines on Use of Anticoagulation in Patients with COVID-19 |
ASH |
2021 |
|
The ADAMTS13-von Willebrand factor axis in COVID-19 patients |
2021 |
||
A living WHO guideline on drugs to prevent covid-19 |
WHO |
2021 |
|
Thrombosis Canada Statement on Astrazeneca COVID-19 Vaccine and Thrombosis |
Thrombosis Canada |
2021 |
|
ISTH Statement on Astrazeneca COVID-19 Vaccine and Thrombosis |
ISTH |
2021 |
|
THROMBOSIS CANADA UPDATED STATEMENT ON ASTRAZENECA VACCINE AND BLOOD CLOTS - Thrombosis Canada seeks to reassure the public regarding blood clot risk and COVID-19 vaccines |
Thrombosis Canada |
2021 |
|
Remdesivir for severe covid-19: a clinical practice guideline |
BMJ Rapid Recommendation |
2020 |
|
IFCC Information Guide on COVID-19 |
IFCC |
2020 |
|
Thromboembolism and Anticoagulant Therapy During the COVID-19 Pandemic: Interim Clinical Guidance from the Anticoagulant Forum |
Anticoagulant Forum |
2020 |
|
ISTH interim guidance on recognition and management of coagulopathy in COVID |
ISTH |
2020 |
|
ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment |
ISTH |
2020 |
|
ISTH interim guidance to recognition and management of coagulopathy in COVID-19 |
ISTH |
2020 |
|
Laboratory haemostasis monitoring in COVID-19 |
ISTH |
2020 |
|
Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |
Chinese Society on Thrombosis and Hemostasis |
2020 |
|
Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic |
Reviewed by UK ITP Forum |
2020 |
|
Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19 |
ISTH SSC |
2020 |
|
Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report |
CHEST |
2020 |
|
The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on Fibrinolysis |
ISTH SSC |
2020 |
|
COVID-19 and its implications for thrombosis and anticoagulation |
ASH |
2020 |
|
A Systematic Approach for Managing Venous Thromboembolism in Patients with COVID-19 |
ISTH |
2020 |
|
Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays |
2020 |
||
Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence based guideline |
2020 |
||
Consensus-Based Clinical Recommendations and Research Priorities for Anticoagulant Thromboprophylaxis in Children Hospitalized for COVID-19 Related Illness |
ISTH SSC |
2020 |
|
Management of the thrombotic risk associated with COVID-19: Guidance for the hemostasis laboratory |
2020 |
||
ISTH DIC subcommittee communication on anticoagulation in COVID-19 |
ISTH SSC |
2020 |
|
Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19 |
2020 |
||
Venous Thromboembolism in COVID-19 |
2020 |
||
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality |
2020 |
||
The hematology laboratory’s response to the COVID-19 pandemic: A scoping review |
2020 |
||
Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis |
2020 |
||
Routine laboratory testing to determine if a patient has COVID-19 |
Cochrane COVID-19 Diagnostic Test Accuracy Group |
2020 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: Communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis |
ISTH SSC |
2023 |
|
Communication from the Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation |
ISTH SSC |
2023 |
|
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management |
2023 |
||
Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care - Second update 2022 |
European Society of Anaesthesiology and Intensive Care |
2023 |
|
Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the ISTH SSC Subcommittee on the Control of Anticoagulation |
ISTH SCC |
2023 |
|
Management of rare inherited bleeding disorders: proposals of the French Reference Centre on Haemophilia and rare coagulation disorders |
French Reference Centre on Haemophilia and rare coagulation disorders |
2023 |
|
Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients |
2023 |
||
Recommendations for standardized definitions, clinical assessment, and future research in pediatric clinically unsuspected venous thromboembolism: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis |
ISTH SSC |
2022 |
|
Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis |
ISTH SSC |
2022 |
|
Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH |
ISTH SSC |
2022 |
|
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) |
ESC and endorsed by ESAIC |
2022 |
|
Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH |
ISTH SSC |
2022 |
|
Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline |
CHEST |
2022 |
|
AGA Clinical Practice Update: Coagulation in Cirrhosis |
AGA |
2019 |
|
Perioperative Management of Direct Oral Anticoagulants in Cardiac Surgery: Practice Recommendations Based on Current Evidence |
2022 |
||
Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH |
ISTH SSC |
2018/2019 |
|
Consensus document of the Spanish Society of Digestives Diseases and the Spanish Society of Thrombosis and Haemostasis on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants |
Spanish Society of Digestives Diseases and Spanish Society of Thrombosis and Haemostasis |
2022 |
|
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia |
2022 |
||
AANMCO position paper ‘Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation’ |
ANMCO |
2022 |
|
ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes |
ANMCO |
2022 |
|
2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association |
AHA / ASA |
2022 |
|
Recommendations for standardized definitions, clinical assessment, and future research in pediatric clinically unsuspected venous thromboembolism: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis |
ISTH SSC |
2022 |
|
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum |
Anticoagulant Forum |
2022 |
|
Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022 |
|
2022 |
|
Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding |
AICE / SISET |
2022 |
|
Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute Cardio Vascular Care and the Asia-Pacific Heart Rhythm Society |
ESC Working Group on Thrombosis |
2022 |
|
Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH |
ISTH SSC |
2022 |
|
Bleeding disorders in implant dentistry: a narrative review and a treatment guide |
2022 |
||
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period |
American College of Gastroenterology and Canadian Association of Gastroenterology |
2022 |
|
Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document |
Multidisciplinary Consensus |
2022 |
|
European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopenic purpura published by the International Society on Thrombosis and Haemostasis |
European Renal Best Practice |
2022 |
|
Electronic diaries in the management of haemophilia gene therapy: Perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH) |
German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH) |
2022 |
|
Management of DOAC in patients undergoing planned surgery or invasive procedure: FCSA position paper |
FCSA |
2021 |
|
Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH |
ISTH SSC |
2021 |
|
European principles of care for women and girls with inherited bleeding disorders |
European Association for Haemophilia and Allied Disorders |
2021 |
|
Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update |
2021 |
||
Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology |
ISTH SSC |
2021 |
|
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation |
ISTH SSC |
2021 |
|
2021 Guidelines on the Diagnosis and Management of VWD |
ASH, ISTH, NHF, WFH |
2021 |
|
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation |
European Heart Rhythm Association |
2021 |
|
Comment: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation |
2021 |
||
Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH |
ISTH SSC |
2020 |
|
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia |
BSH |
2020 |
|
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) |
ECS |
2020 |
|
Standardizing Care to Manage Bleeding Disorders in Adolescents with Heavy Menses—A Joint Project from the ISTH Pediatric/Neonatal and Women's Health SSCs |
ISTH SSC |
2020 |
|
WFH Guidelines for the Management of Hemophilia, 3rd edition |
WFH |
2020 |
|
Investigation and management of erythrocytosi |
2020 |
||
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET |
AICE |
2020 |
|
ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura |
ISTH |
2020 |
|
International Recommendations On The Diagnosis And Treatment Of Acquired Hemophilia A |
2020 |
||
Anticoagulant therapy for splanchnic vein thrombosis |
ISTH SSC |
2020 |
|
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia |
2020 |
||
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura |
ISTH |
2020 |
|
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism |
ASH |
2020 |
|
Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020 |
Canadian Stroke Best Practice Recommendations (CSBPR) |
2020 |
|
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee |
ACC |
2020 |
|
EULAR recommendations for the management of antiphospholipid syndrome in adults |
EULAR |
2019 |
|
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Edition |
American Society for Apheresis |
2019 |
|
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome |
McMaster RARE-Bestpractices project group |
2018 |
|
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when |
European Myeloma Network |
2018 |
|
Review of the NICE guidelines for multiple myeloma |
NCBI |
2017 |
|
Acquired hemophilia A: Updated review of evidence and treatment guidance. |
HTRS |
2017 |
|
Guideline for the diagnosis and management of the rare coagulation disorders. A United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology |
UKHCDO / BCSH |
2014 |
|
Patient self-testing and self-management oforal anticoagulant with vitamin K antagonists: guidance from the British Committee for Standards in Haematology |
BCSH |
2014 |
|
Diagnosis and management of acquired coagulation inhibitors: a guideline form UKHCDO |
UKHCDO / BCSH |
2013 |
|
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) |
UKHCDO / BCSH |
2013 |
|
WFH Guidelines for the Management of Hemophilia, 2nd edition |
WFH |
2012 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders |
French Reference Centre on Haemophilia and Rare Coagulation Disorders |
2023 |
|
WFH GUIDELINES for the MANAGEMENT of HEMOPHILIA – 3rd Edition |
WFH |
2020 |
|
A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH |
ISTH SSC |
2021 |
|
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer |
ASH |
2021 |
|
International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting |
ICSH |
2020 |
|
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory |
2020 |
||
Guideline Papers |
ICSH |
2021 |
|
Recommendations on the Standardization of Critical Results in Hematology – Adult Population |
ICSH |
2016 |
|
Guideline Papers |
BSH |
2021 |